Clinical and direct immunofluorescence characteristics of cutaneous toxicity associated with enfortumab vedotin.

Journal Article (Letter)

Enfortumab vedotin (EV), a novel antibody-drug conjugate approved for metastatic urothelial carcinoma, causes a variety of cutaneous adverse reactions. We present two cases of bullous eruptions following treatment with EV, both demonstrating IgG deposition on direct immunofluorescence (DIF) correlating to the location of nectin-4 in the epidermis. This suggests that the IgG component of EV binding to nectin-4 in keratinocytes is likely a primary contributor to the high rates of cutaneous toxicity.

Full Text

Duke Authors

Cited Authors

  • Penny, CL; Quow, K; Rundle, CW; Al-Rohil, RN; Cardones, AR; Kheterpal, MK; Fresco, AI

Published Date

  • July 2022

Published In

Volume / Issue

  • 187 / 1

Start / End Page

  • 126 - 127

PubMed ID

  • 35048357

Electronic International Standard Serial Number (EISSN)

  • 1365-2133

Digital Object Identifier (DOI)

  • 10.1111/bjd.21022


  • eng

Conference Location

  • England